• Saikosaponins Target Smoothened in Medulloblastoma

  2026-10-09

  A 2022 Journal of Natural Medicines study linked the antitumor activity of saikosaponins B1 and D to functional inhibition of Smoothened-dependent Hedgehog signaling in medulloblastoma models. Its main contribution is mechanistic localization: the compounds blocked pathway activation at or upstream of SMO, while showing weaker evidence for effects on downstream SUFU or GLI2-mediated signaling.

• LGK-974 and PORCN Inhibition: Evidence and Limits

  2026-10-09

  LGK-974 is a research-stage PORCN inhibitor being investigated as a way to reduce ligand-dependent Wnt signaling. The strongest supplied evidence comes from a 2025 preclinical study in Sost-deficient mice and osteoblast models, which reported reduced markers of bone formation and high-bone-mass phenotypes. These findings support further research but do not establish clinical efficacy, long-term safety, or suitability for human sclerosteosis or cancer treatment.

• SP600125: JNK Inhibitor Evidence Guide

  2026-10-08

  SP600125 is a reversible, ATP-competitive JNK inhibitor with reported biochemical activity against JNK1, JNK2, and JNK3. In the CPSIT_0844 study, its pathway relevance is best interpreted as pharmacologic evidence that JNK contributes to inflammatory cytokine signaling, not as proof that JNK is the only downstream mediator.

• Kite-Shaped Molecules and SARS-CoV-2 Entry

  2026-10-08

  Chan, Shafi, and Ford reported a pseudovirus screen that identified structurally related kite-shaped molecules inhibiting SARS-CoV-1 and SARS-CoV-2 entry at a post-attachment stage. The findings support FDA-approved compound collections as tools for hypothesis generation and drug repositioning screening, while remaining preliminary because the study did not establish efficacy against authentic infection or clinical benefit.

• 3-Aminobenzamide: Evidence, Scope and Limits

  2026-10-07

  This source-grounded overview answers five questions about 3-Aminobenzamide (PARP-IN-1): what PARP biology means, what the coronavirus macrodomain study actually showed, how strong the evidence is, how supplier claims should be interpreted, and where applicability ends. The evidence supports a mechanistic role for PARP-mediated ADP-ribosylation in a specific coronavirus host response, but it does not establish clinical efficacy or validate 3-Aminobenzamide as an antiviral treatment.

• PF-04971729 (Ertugliflozin): Evidence Overview

  2026-10-07

  A five-question, source-grounded overview of Ertugliflozin (PF-04971729), covering SGLT2-mediated glucose reabsorption inhibition, the evidence from randomized cardiovascular trials, interpretation of network meta-analysis rankings, and limits on applying the findings beyond patients with type 2 diabetes and heart failure.

• ddATP and the Translational Logic of DNA Termination

  2026-10-06

  A source-grounded perspective on ddATP as a mechanistic probe of DNA synthesis, what mouse-oocyte repair findings reveal, and how translational researchers can distinguish evidence from overinterpretation.

• Bromodomain Inhibitor, (+)-JQ1 and Ferroptosis

  2026-10-06

  Explore how the Bromodomain Inhibitor, (+)-JQ1 connects BET chromatin-reader biology with ferroptosis, ROS, and FSP1 regulation. This evidence-focused guide separates established findings from broader applications in apoptosis, inflammation, and BRDT research.

• Solanesol (B8776): Product Overview

  2026-10-05

  Solanesol is a naturally occurring polyisoprenoid alcohol listed by APExBIO for research use. The available information documents its chemical identity and proposed research scope, but no matched paper evidence was provided to establish biological performance or application-specific efficacy.

• Rucaparib: Interpreting PARP-Linked Cell Death

  2026-10-05

  Rucaparib and AG-014699 offer a focused lens for DNA damage response research. This article develops a distinct framework for separating PARP-dependent DNA repair failure from broader apoptosis signals, informed by recent RNA Pol II findings.

• LGK-974: A Translational Wnt Signaling Strategy

  2026-10-04

  LGK-974 offers a mechanistically focused way to study Porcupine-dependent Wnt secretion and its relevance to Wnt-driven malignancy. This thought-leadership article connects vendor-reported preclinical activity with findings from a 2025 pancreatic cancer study, while defining evidence boundaries, biomarker questions, and translational opportunities without overstating clinical readiness.

• COMET: Deep Learning for LNP Design

  2026-10-03

  Chan and colleagues introduce COMET, a transformer-based model designed to represent complete lipid nanoparticle formulations rather than isolated lipid molecules. Trained on the LANCE dataset, the model predicted formulation performance across several settings and supported the identification of candidates with strong reported expression, while also highlighting important limits around dataset bias, external validation, and the difference between prediction and mechanistic understanding.

• LGK-974: Reading Wnt Biology Beyond Tumor Growth

  2026-10-02

  LGK-974 is a potent PORCN inhibitor for dissecting ligand-dependent Wnt signaling. This article connects pancreatic cancer models with new bone-biology evidence and translates target engagement into more informative assay decisions.

• Radioiodinated Balsalazide for Ulcerative Colitis Imaging

  2026-10-01

  The reference study developed and evaluated radioiodinated balsalazide as a colon-directed radiotracer in normal and ulcerative colitis model mice. Its combination of optimized labeling, 24-hour stability testing, and biodistribution analysis produced a reported uptake of 75 ± 1.90% injected dose per gram in ulcerated mice, while also highlighting important limits for translation beyond preclinical imaging.

• Murine RNase Inhibitor: Assay RNA Reliability

  2026-10-01

  This scenario-based guide explains how Murine RNase Inhibitor SKU K1046 can protect RNA integrity in cell viability, proliferation, and cytotoxicity workflows without being mistaken for a direct viability reagent. It covers inhibitor specificity, low-DTT compatibility, dosing, data interpretation, and practical vendor selection.

8085 records 1/539 page Next 12345 下5页 Last page